Drug Delivery (Jan 2021)

Experimental study on preparation and anti-tumor efficiency of nanoparticles targeting M2 macrophages

  • Zheng Zeng,
  • Yu Liu,
  • Qinglian Wen,
  • Yixian Li,
  • Jing Yu,
  • Qiang Xu,
  • Wenwu Wan,
  • Yu He,
  • Chen Ma,
  • Yan Huang,
  • Helin Yang,
  • Ou Jiang,
  • Fuyu Li

DOI
https://doi.org/10.1080/10717544.2021.1921076
Journal volume & issue
Vol. 28, no. 1
pp. 943 – 956

Abstract

Read online

This study aimed to develop an effective therapy against M2 macrophages and to investigate the effects of imidazole and mannose modified carboxymethyl chitosan-nanoparticles (MIC-NPs) on tumor growth and antitumor immune responses. MIC-NPs were constructed and analyzed through 1H NMR, nano-laser particle size analyzer, and transmission electron microscopy. The nanoparticles were mainly distributed in 75–85 nm, and zeta potential was 1.5 mV. Cytotoxicity studies in vitro and in vivo indicated that MIC-NPs were safe. The targeting effect of MIC-NPs on M2 macrophages was observed through fluorescence microscope and microplate system. The results demonstrated the uptake of a large amount of FITC-loaded MIC-NPs by M2. Cell growth inhibition experiments showed that MIC-NPs significantly inhibited M2 through cell apoptosis. The evaluation of anti-tumor activity in vivo showed that MIC-NPs could accumulate in the tumor site to exert an anti-tumor effect. Flow cytometry showed that the proportion of M2 macrophages at the tumor site in the experimental group was significantly lower than that in the control group, while the Treg cells and cytotoxic T cells (CTL) were found to be increased. PCR detection showed that the cDNA of FIZZ, MR, TGF-β, and arginase, closely related to M2 macrophages, in the experimental group, was significantly lower than that in the control group, but there was no significant difference in the cDNA of Treg cell characteristic Foxp3 between the two groups. These results suggest that MIC-NPs are expected to provide a new and effective treatment for tumor.

Keywords